Approval · Notice of Compliance 10076 · 2009
3TC: Notice of Compliance 10076
Issued March 9, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10076
- Date
- March 9, 2009
- Company
- Glaxosmithkline Shire Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of score to currently approved tablet
- Therapeutic class
- Antiretroviral agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| 3TC | Not yet assigned | — |
Medicinal ingredients
- LAMIVUDINE 150 MG per TAB